88 related articles for article (PubMed ID: 10622045)
21. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
[TBL] [Abstract][Full Text] [Related]
22. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
[TBL] [Abstract][Full Text] [Related]
24. HIV treatment options.
Smith D
AIDS Treat News; 1998 May; (No 294):4-5. PubMed ID: 11365404
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM
AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515
[TBL] [Abstract][Full Text] [Related]
26. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
[TBL] [Abstract][Full Text] [Related]
27. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).
Beck EJ; Mandalia S; Youle M; Brettle R; Fisher M; Gompels M; Kinghorn G; McCarron B; Pozniak A; Tang A; Walsh J; Williams I; Gazzard B
Int J STD AIDS; 2008 May; 19(5):297-304. PubMed ID: 18482958
[TBL] [Abstract][Full Text] [Related]
28. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
Wainberg MA; Sawyer JP; Montaner JS; Murphy RL; Kuritzkes DR; Raffi F
Antivir Ther; 2005; 10(1):13-28. PubMed ID: 15751760
[TBL] [Abstract][Full Text] [Related]
29. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.
Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G
AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883
[TBL] [Abstract][Full Text] [Related]
30. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth.
Szyld EG; Warley EM; Freimanis L; Gonin R; Cahn PE; Calvet GA; Duarte G; Melo VH; Read JS;
AIDS; 2006 Nov; 20(18):2345-53. PubMed ID: 17117021
[TBL] [Abstract][Full Text] [Related]
31. [AIDS; new developments. IV. Changes in primary medical care due to new possibilities of treating HIV-infected patients].
Wigersma L
Ned Tijdschr Geneeskd; 1997 May; 141(21):1051-4. PubMed ID: 9340562
[TBL] [Abstract][Full Text] [Related]
32. HIV protease inhibitors: pharmacologic and metabolic distinctions.
Sommadossi JP
AIDS; 1999 Sep; 13 Suppl 1():S29-40. PubMed ID: 10546783
[TBL] [Abstract][Full Text] [Related]
33. Positioning of HIV-protease inhibitors in clinical practice.
Andreoni M; Perno CF
Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):10-8. PubMed ID: 22338543
[TBL] [Abstract][Full Text] [Related]
34. [HIV protease inhibitors (new possibilities in the treatment of HIV infection and AIDS)].
Bálint GS
Orv Hetil; 1998 Jun; 139(24):1471-4. PubMed ID: 9658865
[TBL] [Abstract][Full Text] [Related]
35. Revisiting monotherapy: heresy or revised orthodoxy?
Huff B
BETA; 2006; 18(2):15-7. PubMed ID: 16610115
[TBL] [Abstract][Full Text] [Related]
36. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1.
Shafer RW; Vuitton DA
Biomed Pharmacother; 1999 Mar; 53(2):73-86. PubMed ID: 10337461
[TBL] [Abstract][Full Text] [Related]
37. Switch studies: a review.
Murphy RL; Smith WJ
HIV Med; 2002 Apr; 3(2):146-55. PubMed ID: 12010362
[TBL] [Abstract][Full Text] [Related]
38. Twenty years of HIV-1 non-nucleoside reverse transcriptase inhibitors: time to reevaluate their toxicity.
Blas-Garcia A; Esplugues JV; Apostolova N
Curr Med Chem; 2011; 18(14):2186-95. PubMed ID: 21521162
[TBL] [Abstract][Full Text] [Related]
39. [Antiretroviral treatment of HIV infection in children].
Ramos Amador JT; Saavedra Lozano J; de José Gómez MI
An Esp Pediatr; 1998 May; 48(5):456-69. PubMed ID: 9656531
[No Abstract] [Full Text] [Related]
40. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens.
Vanangamudi M; Kurup S; Namasivayam V
Curr Opin Pharmacol; 2020 Oct; 54():179-187. PubMed ID: 33202360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
